In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Agenus (AGEN – Research Report), with a price target of $8.00. The company’s shares closed last Friday at $1.60.
Mamtani covers the Healthcare sector, focusing on stocks such as Agenus, Madrigal Pharmaceuticals, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -17.7% and a 28.60% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Agenus with a $8.08 average price target, implying a 405.00% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $3.31 and a one-year low of $1.28. Currently, Agenus has an average volume of 5.63M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
Read More on AGEN:
